WO2017031981A1 - 一种纤体护肤的组合物及其制备方法 - Google Patents

一种纤体护肤的组合物及其制备方法 Download PDF

Info

Publication number
WO2017031981A1
WO2017031981A1 PCT/CN2016/076485 CN2016076485W WO2017031981A1 WO 2017031981 A1 WO2017031981 A1 WO 2017031981A1 CN 2016076485 W CN2016076485 W CN 2016076485W WO 2017031981 A1 WO2017031981 A1 WO 2017031981A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
product
skin care
composition
skin
Prior art date
Application number
PCT/CN2016/076485
Other languages
English (en)
French (fr)
Inventor
刘晓英
Original Assignee
无限极（中国）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 无限极（中国）有限公司 filed Critical 无限极（中国）有限公司
Priority to US15/746,408 priority Critical patent/US20180200181A1/en
Priority to EP16838244.8A priority patent/EP3342417B1/en
Priority to JP2018506987A priority patent/JP2018522923A/ja
Publication of WO2017031981A1 publication Critical patent/WO2017031981A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A61K8/585—Organosilicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/89—Polysiloxanes
    • A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to the field of biotechnology, and in particular to a composition, a preparation method and use thereof, a skin care product containing the composition, and a preparation method thereof.
  • pancreatic lipase inhibitors and appetite suppressants acting on the central nervous system.
  • Appetite suppressants are restricted because they can cause adverse reactions in the nervous system.
  • Pancreatic lipase inhibitor Orlistis He loses weight by inhibiting the activity of pancreatic lipase, thereby inhibiting the decomposition and absorption of fat in food.
  • pancreatic lipase inhibitor Orlistis He loses weight by inhibiting the activity of pancreatic lipase, thereby inhibiting the decomposition and absorption of fat in food.
  • steatorrhea it can cause a lack of fat-soluble vitamins.
  • the central nervous system appetite suppressors lorcaserin and Qsymia became the first FDA-approved diet pills in 13 years, they still have safety uncertainties in the brain and cardiovascular systems. Therefore, there is basically no diet pills with good curative effect and no adverse reactions.
  • the present invention provides a composition, a preparation method and use thereof, a skin care product containing the composition, and a preparation method thereof.
  • the composition or skin care product is safe and non-irritating to the skin, and the obtained skin care composition and preparation can not only increase the secretion level of leptin, but also accelerate the metabolism of body fat; and can increase the content of collagen in the body and improve the relaxation and edema of the skin after lipid-lowering.
  • the invention has been confirmed by experiments to have the effects of skin repair, blood circulation and anti-fatigue.
  • the present invention provides the following technical solutions:
  • the present invention provides a composition comprising the following raw materials in parts by mass:
  • the invention also provides a preparation method of the composition, wherein the raw material of the formula is pulverized and then extracted; the water extraction temperature is 61 ° C to 100 ° C, and the water extraction time is 1 to 4 h; The mass ratio to water is 1:21 to 1:40.
  • the water extraction temperature in the preparation method is from 80 ° C to 100 ° C, and the water extraction time is from 1 to 4 h.
  • the mass ratio of the water-extracted raw material to water in the preparation method is 1:30 to 1:40.
  • the step of cooling, filtering, and collecting the filtrate is further included.
  • the filtration in the preparation method comprises ordinary filtration and vacuum filtration.
  • the ordinary filtration is 100-200 mesh filtration
  • the vacuum suction filtration is to spread the filter paper in a Buchner funnel, and the filter paper is vacuum-filtered by sandwiching 0.3 to 0.6 cm of diatomaceous earth.
  • the vacuum suction filtration is to coat two layers of filter paper in a Buchner funnel, and vacuum filter filtration is carried out by sandwiching 0.3 to 0.6 cm of diatomaceous earth in the middle of the filter paper.
  • the mixture is filtered, cooled, and filtered through 100 mesh, and the residue is filtered off, followed by vacuum filtration.
  • the cooling in the preparation method is cooling to 20 to 30 °C.
  • the invention also provides compositions made by the preparation process.
  • the invention is based on the traditional Chinese medicine "integral, syndrome differentiation, comprehensive" thinking, using natural plant efficacy raw materials, by improving the content of collagen in the body, improving the effect of skin relaxation and edema after lipid-lowering, to achieve the effect of auxiliary slimming.
  • the effect of the composition on the secretion of leptin by adipocytes was studied by ELISA, and it was found that the synergistic use of the components can increase the secretion of leptin.
  • the raw material components can dredge the meridians, so that the blood and blood flow smoothly, and the muscle fascia is qi and blood. Based on this, a slimming composition having a level of fat metabolism and anti-fatigue is obtained.
  • the present invention also provides the use of the composition and/or the composition prepared by the preparation method for preparing a slimming, skin care drug, food, health care product and/or skin care product.
  • the invention also provides the composition and/or the preparation method prepared by the preparation method for improving the secretion level of leptin in adipocytes, treating skin itching, skin repair, removing redness, anti-fatigue, promoting blood circulation, promoting collagen synthesis.
  • the present invention also provides a skin care product comprising the composition and/or the composition prepared by the preparation method and an acceptable excipient in the skin care product.
  • the skin care product is in the form of a cream, cream, serum, toner, lotion or spray.
  • the present invention also provides a method of preparing the skin care product, which is made from the following raw materials:
  • the preparation method comprises the following steps:
  • Step 1 heating and stirring phase A to obtain a first product
  • Step 2 heating and stirring the phase B to obtain a second product
  • Step 3 mixing the first product with the second product, emulsifying, and obtaining a third product
  • Step 4 mixing phase C with the third product to obtain a fourth product
  • Step 5 Take the fourth product, stir and cool, add phase D, phase E, phase F, mix, and cool.
  • the heating temperature is 80 to 85 ° C
  • the heating heating rate is 1 to 2 ° C / min
  • the heating time is 30 to 35 min
  • the rate of agitation is 20 to 60 r/min.
  • the heating temperature is 80 to 85 ° C
  • the heating heating rate is 1 to 2 ° C / min
  • the heating time is 30 to 35 min
  • the rate of agitation is 20 to 60 r/min.
  • the mixing rate of the mixing in the step 3 of the preparation method is 30 to 50 r/min; and the emulsification is homogeneous emulsification for 3 to 5 minutes under the condition of 2500 to 3500 r/min.
  • the mixing rate of the mixing in the step 4 of the preparation method is 30 to 50 r/min.
  • the stirring rate in the step 5 of the preparation method is 30 to 50 r/min; the temperature of the cooling is 40 to 50 ° C, and the rate of the cooling is 1 to 2 ° C / min.
  • the temperature of the cooling in the step 5 of the preparation method is from 30 ° C to 40 ° C.
  • the skin care product provided by the present invention adopts the following specific preparation methods:
  • a phase is put into the oil phase pot, stirred and heated to 80-85 ° C, stirring rate 20-60 r / min, heating rate 1 ⁇ 2 ° C / min, constant temperature 30 ⁇ 35 minutes dissolved completely;
  • phase B is pumped into the water phase pot, stirred and heated to 80-85 ° C, (stirring rate 20 ⁇ 60r / min, heating rate 1 ⁇ 2 ° C / min) constant temperature 30 ⁇ 35 minutes.
  • Emulsification Under stirring (stirring rate 30 ⁇ 50r/min), first pump the phase A in the oil pan into the emulsification pot, then pump all the phase B into the emulsification pot, and homogenize the emulsification at 2500 ⁇ 3500r/min. ⁇ 5min;
  • phase C is put into the emulsification pot under stirring, and the stirring rate is 30 to 50 r/min;
  • the invention also provides a skin care product prepared by the preparation method.
  • the preparation method is prepared by using a slimming cream, and other dosage forms such as essence, toner and lotion can be prepared by using the skin care composition of the invention and the conventional methods and accessories in the skin care field. , sprays, etc.
  • composition provided by the present invention and/or the preparation method can improve the secretion level of leptin in adipocytes, treat skin itching, repair skin, remove redness, anti-fatigue, promote blood circulation, and promote collagen. Synthesis.
  • composition provided by the present invention and/or the composition prepared by the preparation method have slimming and skin care effects.
  • composition and the cream of the invention can be applied to the surface of the human skin by a smear method, such as a calf, an arm, etc., which requires a slimming part, and is gently massaged until absorbed.
  • the invention proves that the skin is safe and non-irritating, and the obtained skin care composition and preparation can not only increase the secretion level of leptin, but also accelerate the metabolism of body fat; at the same time, it can increase the content of collagen in the body and improve the relaxation and edema of the skin after lipid-lowering.
  • the invention has been confirmed by experiments to have the effects of skin repair and blood circulation, and has a skin-beautifying effect at the same time of slimming.
  • Figure 1 is a view showing the infrared image of the calf of the composition prepared in Example 1; wherein Figure 1 (A) shows before the test; Figure 1 (B) shows after the test;
  • FIG. 2 is an infrared imaging diagram of the preparation arm of the composition of Example 1; wherein FIG. 2(A) shows before trial; FIG. 2(B) shows after trial;
  • FIG. 3 is an infrared imaging diagram of a cream calf prepared in Example 4; wherein FIG. 3(A) shows before trial; FIG. 3(B) shows after trial;
  • Fig. 4 is a view showing the infrared imaging of the cream arm of Example 4; wherein Fig. 4(A) shows the test before; and Fig. 4(B) shows the test.
  • the invention discloses a composition, a preparation method and use thereof, a skin care product containing the composition and a preparation method thereof, and those skilled in the art can learn from the contents of the paper and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • the method and the application of the present invention have been described by the preferred embodiments, and it is obvious that the method and application described herein may be modified or appropriately modified and combined without departing from the scope of the present invention. The technique of the present invention is applied.
  • the raw materials used in the examples provided by the present invention can be obtained by commercially available purchase.
  • the sources of the raw materials used in the present invention are shown in Table 1.
  • the names and manufacturers of the instruments used in the present invention are shown in Table 2.
  • the vacuum filtration conditions are as follows: two layers of filter paper are placed in a Buchner funnel, and 0.3 to 0.6 cm of diatomaceous earth is sandwiched between the filter papers for vacuum filtration.
  • the vacuum filtration conditions are as follows: two layers of filter paper are placed in a Buchner funnel, and 0.3 to 0.6 cm of diatomaceous earth is sandwiched between the filter papers for vacuum filtration.
  • the vacuum filtration conditions are as follows: two layers of filter paper are placed in a Buchner funnel, and 0.3 to 0.6 cm of diatomaceous earth is sandwiched between the filter papers for vacuum filtration.
  • Phase A is put into the oil phase pot, stirred and heated to 80 ° C, the stirring rate is 40 r / min, the heating rate is 1 ° C / min, and the temperature is dissolved for 30 minutes;
  • phase B was pumped into a water phase pot, stirred and heated to 80 ° C, (stirring rate 40 r / min, heating rate 1 ° C / min) and kept at a constant temperature for 30 minutes.
  • Emulsification Under stirring (stirring rate 30r/min), the phase A in the oil pan is first drawn into the emulsification pot, and then the phase B is all pumped into the emulsification pot, and homogeneously emulsified at 2500 r/min for 3 min;
  • Phase A is put into the oil phase pot, stirred and heated to 82 ° C, the stirring rate is 20 r / min, the heating rate is 2 ° C / min, and the temperature is dissolved for 35 minutes;
  • phase B was pumped into a water phase pot, stirred and heated to 82 ° C, (stirring rate 20 r / min, heating rate 2 ° C / min) and kept at a constant temperature for 35 minutes.
  • Emulsification under stirring (stirring rate 40r/min), firstly pump the phase A in the oil pan into the emulsification pot, then pump all the phase B into the emulsification pot, and homogenize and emulsifie for 4 min at 3000 r/min;
  • phase C is put into the emulsification pot under stirring, and the stirring rate is 40 r/min;
  • Phase A is put into the oil phase pot, stirred and heated to 85 ° C, the stirring rate is 60 r / min, the heating rate is 1 ° C / min, and the temperature is dissolved for 32 minutes;
  • phase B was pumped into a water phase pot, stirred and heated to 85 ° C, (stirring rate 60 r / min, heating rate 2 ° C / min) and kept at a constant temperature for 32 minutes.
  • Emulsification under stirring (mixing rate 50r/min), firstly pump the phase A in the oil pan into the emulsification pot, then pump all the phase B into the emulsification pot, and homogenize and emulsifie for 5 min at 3500 r/min;
  • BP3100S electronic balance SARTORIUS company; SZCL intelligent temperature control heating stirrer: Gongyi City Yuhua Instrument Co., Ltd.; SHB-III type circulating water vacuum pump; CO 2 incubator (USA, M-1815TC), liquid scintillation counter (state-run 262 factory, FJ-2107 type), desktop frozen high-speed centrifuge Sigma 4K15 is the product of American Sigma company; vacuum freeze-drying instrument ADVANTAGE is the product of American VI ⁇ company; Multiskan GO microplate reader: Thermo.
  • Human skin fibroblast CCD-966SK in MEM medium (containing 10% FBS, 1% cyan-streptomycin, 1% non-essential amino acid and 1% sodium pyruvate) at 5% CO2, 37 °C Culture, change every 2 to 3 days. Effect on cell proliferation: 1 ⁇ 104 CCD-966SK cells per well were seeded in 96-well plates, and samples (prepared in MEM whole medium containing 10% fetal bovine serum) were added, and the total volume per well was 100 ⁇ L. The collagen content was determined using a collagen assay kit (Sircol Collagen assay).
  • Example 1 The effects of the slimming composition on the collagen synthesis of human skin fibroblast CCD-966SK were obtained by measuring Example 1, Example 2, and Example 3.
  • the experimental blank group contained no plant extracts.
  • the experimental results are shown in Table 6. The results showed that the plant extracts of Example 1, Example 2 and Example 3 significantly promoted the collagen synthesis of CCD-966SK cells (P ⁇ 0.05).
  • Example 1 Example 2
  • Example 3 Effect of Preparation of Slimming Composition on Secretion of Leptin by Adipocytes
  • D-MEM/F-12 (1:1) dry powder plus deionized water 850mL, after all dissolved, add NaHCO 3 2.44g, HEPES 3.15g, dilute to 1000ml, adjust the pH to 7.2 with 0.1N HCL and NaOH, The 0.22 um filter was filtered and sterilized, and stored at 4 ° C for use.
  • 10% inactivated calf serum was used as a proliferation medium or aseptically supplemented with 10% inactivated fetal bovine serum as a basal medium.
  • Insulin (10 ug/mL), dexamethasone (1 uM), and IBMX (0.5 mM) were added to the basal medium, and the cells were sterilized by filtration through a 0.22 um filter and stored at 4 °C. 10% inactivated fetal bovine serum and double antibody were separately aseptically used as differentiation medium I.
  • a medium having a final insulin concentration of 10 ug/ml was obtained.
  • the cells were sterilized by filtration through a 0.22 um filter and stored at 4 °C. 10% inactivated fetal bovine serum was added as a differentiation medium II aseptically.
  • the 3T3-L1 pre-adipocyte cell line was cultured in a proliferation medium containing 10% calf serum at 37 ° C in a 5% CO 2 incubator, and the solution was changed every 2 to 3 days, and the cells were grown to 50% to 60%. Subculture.
  • the induced differentiation of pre-adipocytes was cultured according to the classical cocktail method. The cell density was adjusted to 2 ⁇ 10 5 /ml, and the cells were subcultured in a 6-well culture plate or a 24-well culture plate.
  • the medium was changed once every 2 to 3 days, until the cell monolayer was fused, and then changed to the basal medium containing 10% fetal bovine serum for 2 days, and then induced to induce differentiation by induction fluid I for 48 hours, after which the induction medium II was continued. After 48 hours, the cells were cultured in basal medium containing 10% fetal bovine serum, and changed every 48 hours. After 7 days, more than 90% of the cell morphology is nearly round, and the cytoplasm is filled with lipid droplets, which are differentiated mature fat cells.
  • mice healthy guinea pigs, SPF/VAF grade, half male and half female, weighing 250 ⁇ 10g. Provided by Beijing Jinmuyang Experimental Animal Breeding Co., Ltd., animal certificate number: SCXK (Beijing) 2010-0001. Breeding environment: Beijing Jin Muyang Experimental Animal Breeding Co., Ltd. Farm.
  • the test article was applied as a large dose, a medium dose group and a low dose group, respectively, with 0.15 ml/1 cm 2 , 0.1 ml/1 cm 2 , and 0.05 ml/1 cm 2 .
  • the model control group was topically applied with 0.1 ml/1 cm 2 of distilled water.
  • the guinea pig was scratched on the back of the right hind paw with a coarse sandpaper, the area was about 1 cm 2 , and the drug was applied once more. After 10 minutes of the last application, 0.01% of histamine phosphate was dropped at the abrasion site, and every 3 drops thereafter. The increments were in increments of 0.01%, 0.02%, 0.03%, 0.04%, etc., each time being 0.05 mL. Until the guinea pig turned back to the right hind paw, the total amount of histamine phosphate dripped when the guinea pig turned back to the right hind paw was the itch threshold. The itch thresholds of each group were calculated and the differences between the groups were compared.
  • the slimming extract prepared in Example 1 and the slimming cream prepared in Example 4 can effectively improve the itching threshold of histamine phosphate, and prove its efficacy in relieving skin inflammation and relieving itching.
  • the inventors prepared the slimming composition using Example 2 and Example 3, and prepared the slimming cream in Example 5 and Example 6. The above experiment was repeated to obtain the same effect, and the slimming extract was prepared in the same manner as in Example 1, Example 4 There was no significant difference in the preparation of the obtained slimming cream (P>0.05).
  • mice healthy guinea pigs, SPF/VAF grade, 36, half male and half female, weighing 250 ⁇ 10g. Provided by Beijing Jinmuyang Experimental Animal Breeding Co., Ltd., animal certificate number: SCXK (Beijing) 2010-0001. Breeding environment: Beijing Jin Muyang Experimental Animal Breeding Co., Ltd. Farm.
  • Acetone and ether are all products of Beijing Chemical Plant. Skin moisture tester,
  • the test article was applied as a high dose group, a medium dose group and a low dose group with 0.15 g/1 cm 2 , 0.1 g/1 cm 2 and 0.05 g/1 cm 2 .
  • the blank control group and the model control group were topically applied with 0.1 ml/1 cm 2 of distilled water.
  • 2.2 36 guinea pigs were taken. The neck was shaved 1 day before the experiment, and the area was about 2 ⁇ 2 cm 2 .
  • the rats were randomly divided into blank control group, model control group, high dose group, medium dose group and low dose group.
  • the model control group of guinea pigs were given distilled water and applied to the hair removal area. The skin water content of the guinea pig hair was measured 20 minutes after the sample was administered on the 5th day, the difference between the groups was compared, and the water dispersion loss protection rate was calculated.
  • the effect of the sample on the skin moisture content of the skin dehydration model can provide an experimental basis for evaluating the repairing effect of the sample on allergic skin.
  • Water dispersibility loss rate (%) (medical group skin water content - model group skin water content) / blank control group skin water content ⁇ 100
  • the slimming cream prepared in Example 1 and the slimming cream prepared in Example 4 had remarkable effects on skin repair.
  • the inventors prepared the slimming preparation by using Example 2 and Example 3, and the preparation of the slimming cream of Example 5 and Example 6. The above experiment was repeated to obtain the same effect, and the slimming extract was prepared in the same manner as in Example 1, and the preparation of Example 4 was carried out. There was no significant difference in the obtained slimming cream (P>0.05). It is indicated that the preparation prepared by the invention has a good repairing effect.
  • test material 1.1 experimental sample: Example 1 preparation of slimming extract, Example 4 preparation of slimming cream;
  • the test article was applied as a large dose, a medium dose group and a low dose group at 0.15 g/1 cm 2 , 0.1 g/1 cm 2 , and 0.05 g/1 cm 2 .
  • the blank control group and the model control group were topically applied with 0.1 g/1 cm 2 of distilled water.
  • the evaluation results show that the preparation composition and the cream preparation of the present invention have the effects of relieving soreness and anti-fatigue, and the samples prepared in Example 2, Example 3, Example 5 and Example 6 are repeated to obtain the same result.
  • the preparation of the slimming extract of Example 1 and the slimming cream prepared in Example 4 were not significantly different (P>0.05).
  • Smear method smear on the calf and arm, 2 times a day, once in the morning and evening, for 4 weeks.
  • the blood circulation nourishing effect of skin care products can be evaluated by infrared thermography.
  • the infrared thermography image of the skin can detect the blood flow velocity and temperature of the test site, which can reflect the operation of blood and blood, and the blood flow velocity is fast and the temperature High, the blood is good.
  • the blood circulation effect of the sample can be evaluated by comparing the infrared imaging images before and after the trial.
  • Example 1 Preparation of Compositions Infrared Imaging of the Calf and the Arms As shown in FIG. 1 and FIG. 2, the infrared embossing of the calf and the lower arm of the preparation of the cream of Example 4 is shown in FIG. 3 and FIG. 4 .
  • Example 1 and Example 4 had good blood circulation promoting effects, and the same samples were prepared for the samples prepared in Example 2, Example 3, Example 5 and Example 6, and the results were the same as above. There was no significant difference (P>0.05) between the preparation of the slimming extract and the preparation of the slimming cream prepared in Example 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

一种具有减肥护肤作用的组合物，其包含如下重量份的原料：燕麦 5-10份，苦橙花 1-3份，莲叶 1-3份，陈皮 3-5份。其制备方法为将所述原料粉碎后，用水提取而得。

Description

[根据细则37.2由ISA制定的发明名称]　一种纤体护肤的组合物及其制备方法
本申请要求于2015年08月24日提交中国专利局、申请号为201510527307.1、发明名称为“一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及生物技术领域，特别涉及一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法。
背景技术
随着人们生活水平的提高，肥胖成为影响人们生活质量的原因之一，尤其是对于女性而言。工作生活压力大、饮食不规律、女性生产原因、运动量少等等成为目前肥胖的主要成因。肥胖不仅影响美观，还容易影响健康。
目前消除肥胖的产品很多，分为内服药品及外用制剂。市售内服的减肥药品有两大类，胰脂肪酶抑制剂和作用于中枢神经系统的食欲抑制剂，食欲抑制剂由于可引起神经系统不良反应而被限制使用，胰脂肪酶抑制剂奥利司他通过抑制胰脂肪酶活性，进而抑制食物中脂肪的分解吸收而减肥。但因其会引起脂肪泻，可造成脂溶性维生素缺乏。最近还有报道其可引起肝功能损害。尽管中枢神经系统食欲抑制剂lorcaserin和Qsymia成为了FDA 13年来首次批准的减肥药，但其仍然存在大脑中枢和心血管系统等方面的安全不确定性。因此目前疗效好且无不良反应的减肥药基本没有。
外用减肥制剂，如瘦身霜、纤体霜等被炒得火热。但是市售瘦身霜等外用制剂的功效不容乐观，一些产品主要是靠辣椒素给皮肤带来“火辣”的感觉从而让消费者误认为脂肪在燃烧。还有的产品可以促进皮肤排汗，改善水肿从而起到瘦身的功效。由于其治标不治本的特性使其功效短暂易反弹。更甚者对皮肤会造成一定的伤害，带来皮肤松弛或老化等副作用。
因此，获得一种纤体瘦身效果好且持久，同时具有美肤功效的外用制剂具有重要的现实意义。
发明内容
有鉴于此，本发明提供一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法。该组合物或护肤品对皮肤安全无刺激，所得护肤组合物及制剂既能提高瘦素分泌水平，加速体脂代谢；又能够提高体内胶原蛋白的含量，改善降脂后皮肤的松弛、浮肿状态的功效，达到健康纤体，协同增效的目的。本发明经实验证实还兼具皮肤修复及活血、抗疲劳的功效。
为了实现上述发明目的，本发明提供以下技术方案：
本发明提供了一种组合物，包括如下质量份的原料：
Figure PCTCN2016076485-appb-000001
本发明还提供了所述组合物的制备方法，取配方量的所述原料粉碎后，水提；水提的温度为61℃～100℃，水提的时间为1～4h；水提的原料与水的质量比为1:21～1:40。
更优选的，所述制备方法中水提的温度为80℃～100℃，水提的时间为1～4h。
更优选的，所述制备方法中所述水提的原料与水的质量比为1:30～1:40。
作为优选，所述制备方法中在水提之后还包括冷却、过滤、收集滤液的步骤。
作为优选，所述制备方法中所述过滤包括普通过滤和真空抽滤。
在作为优选，所述普通过滤为100～200目过滤；
作为优选，所述真空抽滤为在布氏漏斗里铺滤纸，滤纸中间夹0.3～0.6cm硅藻土进行真空抽滤。
作为优选，所述真空抽滤为在布氏漏斗里铺两层滤纸，滤纸中间夹0.3～0.6cm硅藻土进行真空抽滤。
作为优选，过滤为提取液冷却后，100目过滤，滤出渣后进行真空抽滤。
作为优选，所述制备方法中所述冷却为冷却至20～30℃。
本发明还提供了所述制备方法制得的组合物。
本发明依据传统中医“整体、辨证、综合”思想，采用天然的植物功效原料，通过提高体内胶原蛋白的含量，改善降脂后皮肤的松弛、浮肿状态的功效，达到辅助纤体的功效。同时，通过ELISA法研究组合物对脂肪细胞分泌瘦素的影响，发现各组分协同使用可以使瘦素分泌提高。此外，本原料成分可疏通经络，使气血流畅，肌肉筋膜得气血营养。基于此得到一种以具有调节脂肪代谢水平、抗疲劳的纤体组合物。
本发明还提供了所述组合物和/或所述制备方法制得的组合物在制备纤体、护肤的药物、食品、保健品和/或护肤品中的应用。
本发明还提供了所述组合物和/或所述制备方法制得的组合物在制备提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白合成的药物、食品、保健品和/或护肤品中的应用。
本发明还提供了一种护肤品，包括所述组合物和/或所述制备方法制得的组合物以及护肤品中可接受的辅料。
在本发明的一些具体实施方案中，所述护肤品的剂型为膏剂、霜剂、精华、爽肤水、乳液或喷雾剂。
本发明还提供了所述护肤品的制备方法，其由如下质量份的原料制成：
Figure PCTCN2016076485-appb-000002
Figure PCTCN2016076485-appb-000003
所述制备方法包括如下步骤：
步骤1：将A相加热、搅拌，获得第一产品；
步骤2：将B相加热、搅拌，获得第二产品；
步骤3：将所述第一产品与第二产品混合，乳化，获得第三产品；
步骤4：将C相与所述第三产品混合，获得第四产品；
步骤5：取所述第四产品，搅拌、降温，加入D相、E相、F相，混合，冷却，即得。
作为优选，所述制备方法步骤1中所述加热的温度为80～85℃，所述加热的升温速率为1～2℃/min；所述加热的时间为30～35min；步骤1中所述搅拌的速率为20～60r/min。
作为优选，所述制备方法步骤2中所述加热的温度为80～85℃，所述加热的升温速率为1～2℃/min；所述加热的时间为30～35min；步骤1中所述搅拌的速率为20～60r/min。
作为优选，所述制备方法步骤3中所述混合的搅拌速率为30～50r/min；所述乳化为在2500～3500r/min的条件下均质乳化3～5min。
作为优选，所述制备方法步骤4中所述混合的搅拌速率为30～50r/min。
作为优选，所述制备方法步骤5中所述搅拌的速率为30～50r/min；所述降温的温度为40～50℃，所述降温的速率为1～2℃/min。
作为优选，所述制备方法步骤5中所述冷却的温度为30℃～40℃。
作为优选，本发明提供的护肤品采用如下具体制备方法：
Figure PCTCN2016076485-appb-000004
Figure PCTCN2016076485-appb-000005
(1)A相投入油相锅，搅拌升温至80～85℃，搅拌速率20～60r/min，升温速率1～2℃/min，恒温30～35分钟溶解完全；
(2)将B相抽入水相锅，搅拌升温至80～85℃，(搅拌速率20～60r/min，升温速率1～2℃/min)恒温30～35分钟。
(3)乳化：在搅拌下(搅拌速率30～50r/min)，先将油锅中的A相抽入乳化锅，再将B相全部抽入乳化锅，2500～3500r/min均质乳化3～5min；
(4)在搅拌下将C相投入乳化锅，搅拌速率30～50r/min；
(5)在搅拌下，搅拌速率30～50r/min，降温至40～50℃，降温速率1～2℃/min，依次加入D、E、F相，搅拌均匀；
(6)搅拌冷却至40℃以下，出料，即得。
本发明还提供了所述制备方法制得的护肤品。
在本发明的一些具体实施方案中，所述制备方法制备得到的是纤体膏霜，利用本发明护肤组合物及护肤品领域常规方法及辅料也可以制备得到其他剂型，如精华、爽肤水、乳液、喷雾剂等。
实验证明，本发明提供的所述组合物和/或所述制备方法制得的组合物能够提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白的合成。
综上，本发明提供的所述组合物和/或所述制备方法制得的组合物具有纤体、护肤的功效。
本发明提供的护肤品推荐使用方法为：本发明组合物及膏霜均可以涂抹方法施于人体皮肤表面，如小腿、小臂等需要纤体部位，轻轻按摩直至吸收。
本发明经实验证实对皮肤安全无刺激，所得护肤组合物及制剂既能提高瘦素分泌水平，加速体脂代谢；同时又能够提高体内胶原蛋白的含量，改善降脂后皮肤的松弛、浮肿状态的功效，达到健康纤体，协同增效的目的。本发明经实验证实还兼具皮肤修复及活血的功效，在纤体的同时起到美肤效果。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示实施例1制备组合物小腿红外成像图；其中，图1(A)示试用前；图1(B)示试用后；
图2示实施例1制备组合物小臂红外成像图；其中，图2(A)示试用前；图2(B)示试用后；
图3示实施例4制备膏霜小腿红外成像图；其中，图3(A)示试用前；图3(B)示试用后；
图4示实施例4制备膏霜小臂红外成像图；其中，图4(A)示试用前；图4(B)示试用后。
具体实施方式
本发明公开了一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法，本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合，来实现和应用本发明技术。
本发明提供的实施例所用原料均可通过市售购买获得，本发明使用原料的来源见表1，本发明所用的仪器名称及厂家见表2。
表1原料及其来源
Figure PCTCN2016076485-appb-000006
Figure PCTCN2016076485-appb-000007
表2仪器名及购买厂家
名称 型号 厂家
恒温水浴锅 HH·S1-M 北京长安科学仪器厂
智能控温加热搅拌器 SZCL 巩义市予华仪器有限公司
循环水式真空泵 SHB-Ⅲ 郑州长城科工贸有限公司
下面结合实施例，进一步阐述本发明：
实施例1本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取，混匀；
燕麦50g，苦橙花20g，莲叶20g，陈皮50g
(2)加水提取，原料与水的质量比为1：21，61℃提取3小时；
(3)将步骤(2)得到的提取液冷却至20℃，100目过滤，滤出渣后进行真空抽滤，收集滤液，即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸，滤纸中间夹0.3～0.6cm硅藻土进行真空抽滤。
实施例2本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取，混匀；
燕麦65g，苦橙花30g，莲叶10g，陈皮30g
(2)加水提取，原料与水的质量比为1：30，100℃提取1小时；
(3)将步骤(2)得到的提取液冷却至25℃，200目过滤，滤出渣后进行真空抽滤，收集滤液，即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸，滤纸中间夹0.3～0.6cm硅藻土进行真空抽滤。
实施例3本发明植物组合物的制备
(1)下述原料粉碎后按所述重量份配比称取，混匀；
燕麦100g，苦橙花10g，莲叶30g，陈皮40g
(2)加水提取，原料与水的质量比为1：40，80℃提取4小时；
(3)将步骤(2)得到的提取液冷却至30℃，100目过滤，滤出渣后进行真空抽滤，收集滤液，即得。
所述步骤(3)中真空抽滤条件为在布氏漏斗里铺两层滤纸，滤纸中间夹0.3～0.6cm硅藻土进行真空抽滤。
实施例4本发明纤体膏霜的制备
组方及用量：
表3组方及用量
Figure PCTCN2016076485-appb-000008
Figure PCTCN2016076485-appb-000009
膏霜制备方法：
(1)A相投入油相锅，搅拌升温至80℃，搅拌速率40r/min，升温速率1℃/min，恒温30分钟溶解完全；
(2)将B相抽入水相锅，搅拌升温至80℃，(搅拌速率40r/min，升温速率1℃/min)恒温30分钟。
(3)乳化：在搅拌下(搅拌速率30r/min)，先将油锅中的A相抽入乳化锅，再将B相全部抽入乳化锅，2500r/min均质乳化3min；
(4)在搅拌下将C相投入乳化锅，搅拌速率30r/min；
(5)在搅拌下，搅拌速率30r/min，降温至40℃，降温速率1℃/min，依次加入D、E、F相，搅拌均匀；
(6)搅拌冷却至40℃，出料，即得。
实施例5本发明纤体膏霜的制备
组方及用量：
表4组方及用量
Figure PCTCN2016076485-appb-000010
Figure PCTCN2016076485-appb-000011
膏霜制备方法：
(1)A相投入油相锅，搅拌升温至82℃，搅拌速率20r/min，升温速率2℃/min，恒温35分钟溶解完全；
(2)将B相抽入水相锅，搅拌升温至82℃，(搅拌速率20r/min，升温速率2℃/min)恒温35分钟。
(3)乳化：在搅拌下(搅拌速率40r/min)，先将油锅中的A相抽入乳化锅，再将B相全部抽入乳化锅，3000r/min均质乳化4min；
(4)在搅拌下将C相投入乳化锅，搅拌速率40r/min；
(5)在搅拌下，搅拌速率40r/min，降温至45℃，降温速率2℃/min，依次加入D、E、F相，搅拌均匀；
(6)搅拌冷却至35℃，出料，即得。
实施例6本发明纤体膏霜的制备
组方及用量：
表5组方及用量
Figure PCTCN2016076485-appb-000012
Figure PCTCN2016076485-appb-000013
膏霜制备方法：
(1)A相投入油相锅，搅拌升温至85℃，搅拌速率60r/min，升温速率1℃/min，恒温32分钟溶解完全；
(2)将B相抽入水相锅，搅拌升温至85℃，(搅拌速率60r/min，升温速率2℃/min)恒温32分钟。
(3)乳化：在搅拌下(搅拌速率50r/min)，先将油锅中的A相抽入乳化锅，再将B相全部抽入乳化锅，3500r/min均质乳化5min；
(4)在搅拌下将C相投入乳化锅，搅拌速率50r/min；
(5)在抽真空搅拌下，搅拌速率50r/min，降温至50℃，降温速率2℃/min，依次加入D、E、F相，搅拌均匀；
(6)在抽真空搅拌冷却至30℃，出料，即得。
实施例7功效实验
一、实施例1、实施例2、实施例3制备所得纤体组合物对CCD-966SK细胞合成胶原蛋白的影响
1.1试验材料
人类皮肤纤维母细胞CCD-966SK台湾食品工业研究所；MEM细胞培养液(Minimum Essential Medium，Earle's)、胎牛血清、非必需氨基酸、丙酮酸钠Invitrogen 公司；二甲基亚砜Sigma公司；WST-1(水溶性四唑盐)Abnova公司；胶原检测试剂盒Biocolor公司；实施例制备样品
1.2主要仪器
BP3100S电子天平：SARTORIUS公司；SZCL智能控温加热搅拌器：巩义市予华仪器有限公司；SHB-Ⅲ型循环水式真空泵；CO2培养箱(美国,M-1815TC)，液体闪烁计数仪(国营二六二厂，FJ-2107型)，台式冷冻高速离心机Sigma 4K15为美国Sigma公司产品；真空冷冻干燥仪ADVANTAGE为美国Ⅵ潞公司产品；Multiskan GO酶标仪：Thermo。
1.3实验方法
将人类皮肤纤维母细胞CCD-966SK，以MEM培养基(其中含10％FBS、1％青－链霉素、1％非必需氨基酸以及1％丙酮酸钠)在5％CO2、37℃条件下培养，每2～3d换液。对细胞增殖的作用：按照每孔1×104个CCD-966SK细胞接种于96孔板，并加入样品(以含10％胎牛血清的MEM全培养液配制)，每孔总体积100μL。胶原蛋白的含量采用胶原蛋白检测试剂盒(Sircol Collagen assay)测定。
1.4实验结果
测定实施例1、实施例2、实施例3得到纤体组合物对人类皮肤纤维母细胞CCD-966SK合成胶原蛋白的影响。实验空白组不含植物提取物。实验结果见表6。结果表明，实施例1、实施例2、实施例3得到植物提取物对CCD-966SK细胞胶原蛋白合成具有显著的促进作用(P＜0.05)。
表6实验结果
样品名称 胶原蛋白浓度(mg/mL)
空白组 0
实施例1 0.02
实施例2 0.03
实施例3 0.03
二、实施例1、实施例2、实施例3制备纤体组合物对脂肪细胞分泌瘦素的影响
1、增殖培养基的配制(1000ml)
D-MEM/F-12(1:1)干粉加去离子水850mL，待全部溶解后加入NaHCO32.44g、HEPES 3.15g，定容至1000ml，用0.1N的HCL和NaOH调节pH到7.2，0.22um滤膜过滤除菌分装，4℃保存备用。用时无菌添加10％灭活小牛血清作为增殖培养基或无菌添加10％灭活胎牛血清作为基础培养基。
2、分化培养基Ⅰ配制(100ml)
向基础培养基中添加胰岛素(10ug/mL)、地塞米松(1uM)、IBMX(0.5mM)，经0.22um滤膜过滤除菌分装，储存于4℃。用时分别无菌添加10％灭活胎牛血清和双抗作为分化培养基Ⅰ。
3、分化培养基Ⅱ配制(100ml)
向基础培养基中添加胰岛素1mg，制成100mL分化培养基，得到胰岛素终浓度为10ug/ml的培养基。经0.22um滤膜过滤除菌分装，储存于4℃。用时无菌添加10％灭活胎牛血清作为分化培养基Ⅱ。
4、细胞培养
3T3-Ll前脂肪细胞株用含10％小牛血清的增殖培养基在37℃、5％CO2培养箱中培养，每2～3天换液一次，细胞长至50％～60％左右进行传代培养。前脂肪细胞的诱导分化按经典鸡尾酒法进行培养。调节细胞密度至2×105个/m1，定量接种于6孔培养板或24孔培养板中传代培养。2～3天更换培养基一次，直至细胞单层融合后，换为含10％胎牛血清的基础培养基培养2天，之后换为诱导液Ⅰ诱导细胞分化48小时，此后换诱导液Ⅱ继续培养，再48小时后，用含10％胎牛血清的基础培养基培养细胞，每48小时换液一次。7天后，90％以上的细胞形态近于圆形，胞浆内充满脂滴，即为分化成熟的脂肪细胞。
5、ELISA法测定不同浓度Act对脂肪因子的影响
每组设定3个平行孔。第10天收集细胞上清，按试剂盒说明测定瘦素含量。设定对照组，在分化第8天给药。
实施例1至3制备产品刺激成熟脂肪细胞分泌瘦素的结果见表7，由表7可以看出实施例1至3制备产品可以刺激成熟脂肪细胞分泌瘦素，瘦素释放水平逐渐增加。
表7实验结果
Figure PCTCN2016076485-appb-000014
三、实施例1制备纤体提取物及实施例4制备纤体膏霜对豚鼠皮肤瘙痒模型的消炎
作用实验
1试验材料1.1实验样品：实施例1制备纤体提取物、实施例4制备纤体膏霜
1.2实验动物：健康豚鼠，SPF/VAF级，雌雄各半，体重250±10g。由北京金牧阳实验动物养殖有限责任公司提供，动物合格证号：SCXK(京)2010-0001。饲养环境：北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂：磷酸组胺，Sigma公司产品。
2试验方法
2.1剂量设计：受试品以0.15ml/1cm2、0.1ml/1cm2、0.05ml/1cm2局部涂抹分别作为大剂量、中剂量组和小剂量组。模型对照组给予0.1ml/1cm2蒸馏水局部涂抹。
2.2磷酸组织胺致痒法：取豚鼠36只，于实验前1天右后足背剃毛，随机分组：模型对照组、大剂量组、中剂量组和小剂量组。连续3天于剃毛处分别均匀涂抹相应剂量受试品，模型对照组给予蒸馏水涂抹。实验第3天，精密称取磷酸组胺适量，临用前 以蒸馏水配成0.01％、0.02％、0.03％、0.04％、0.05％、0.06％、0.07％、0.08％、0.09％、0.10％梯度浓度备用。用粗砂纸将豚鼠右后足背剃毛处擦伤，面积约1cm2，局部再涂药1次，于末次涂药10min后在擦伤处滴0.01％磷酸组胺0.05mL，以后每隔3分钟依0.01％、0.02％、0.03％、0.04％……递增浓度，每次均为0.05mL。直到出现豚鼠回头舔右后足，以最后出现豚鼠回头舔右后足时所滴取的磷酸组胺总量为致痒阈。计算各组致痒阈并比较组间的差异性。
3试验结果
结果显示，使用磷酸组胺致痒后，豚鼠出现回头舔右后足行为。使用受试品涂抹致痒部位后，大剂量组受试品可显著提高豚鼠磷酸组胺致痒阈，与模型对照组比较有显著性差异(P<0.05)。结果见表8。
表8样品对豚鼠磷酸组胺致痒反应的影响(x±s，n＝6)
Figure PCTCN2016076485-appb-000015
注：与模型对照组比较，*P<0.05。
4试验结论
实施例1制备纤体提取物、实施例4制备所得纤体膏霜可有效的提高磷酸组胺致痒阈，证实了其缓解皮肤炎症、止痒的功效。
发明人用实施例2、实施例3制备纤体组合物、实施例5、实施例6制备纤体膏霜重复上述实验，得到相同的效果，与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P＞0.05)。
四、实施例1及实施例4制备所得制剂皮肤修复作用功效评价
1试验材料1.1实验样品：实施例1制备纤体提取物、实施例4制备纤体膏霜
1.2实验动物：健康豚鼠，SPF/VAF级，36只，雌雄各半，体重250±10g。由北京金牧阳实验动物养殖有限责任公司提供，动物合格证号：SCXK(京)2010-0001。饲养环境：北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂及仪器：丙酮、乙醚，均为北京化工厂产品。皮肤含水量检测仪，
2试验方法
2.1剂量设计：受试品以0.15g/1cm2、0.1g/1cm2、0.05g/1cm2局部涂抹作为大剂量 组、中剂量组和小剂量组。空白对照组和模型对照组给予0.1ml/1cm2蒸馏水局部涂抹。
2.2取豚鼠36只，于实验前1天颈背部剃毛，面积约为2×2cm2，随机分组：空白对照组、模型对照组、受试大剂量组、中剂量组和小剂量组。除空白对照组豚鼠，其余各组取丙酮：乙醚＝1:1混合液150μl滴于去毛处，10分钟后分别取相应样品涂抹于去毛部位，一天2次，连续5天，空白对照组和模型对照组豚鼠给予蒸馏水涂抹于去毛处。于第5天给予样品后20分钟测量豚鼠脱毛处皮肤含水量，比较组间差异，并计算水分散失保护率。
样品对皮肤脱水模型皮肤含水量的影响，可以为评价样品对过敏皮肤的修复功效提供实验依据。
水分散失保护率(％)＝(用药组皮肤含水量-模型组皮肤含水量)/空白对照组皮肤含水量×100
3试验结果
结果显示，豚鼠皮肤脱水后，模型对照组豚鼠皮肤脱水率为50.75％。使用受试品涂抹后，实施例1制备纤体植物组合物、实施例4制备纤体膏霜大剂量组可显著提高豚鼠皮肤含水量，与模型对照组比较有显著性差异(P<0.05)。结果见表9。
表9对过敏后皮肤的修复作用(x±s,n＝6)
Figure PCTCN2016076485-appb-000016
4试验结论
实施例1制备纤体组合物、实施例4制备所得纤体膏霜对皮肤修复功效明显。
发明人用实施例2、实施例3制备纤体制剂、实施例5、实施例6制备纤体膏霜重复上述实验，得到相同的效果，与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P＞0.05)。说明本发明制备所得制剂具有良好的修复作用。
五、实施例1及实施例4制备所得制剂去红肿功效评价
1试验材料1.1实验样品：实施例1制备纤体提取物、实施例4制备纤体膏霜；
1.2实验动物：SD大鼠，SPF/VAF级，36只，雌雄各半，体重180±10g。由北京金牧阳实验动物养殖有限责任公司提供，动物合格证号：SCXK(京)2010-0001。饲养环境：北京金牧阳实验动物养殖有限责任公司养殖场。
1.3试剂及仪器：anti-DNP IgE、DNP-HAS、伊文思蓝均为Sigma公司产品；丙酮为北京化工厂产品。RT-6000酶标仪为雷杜公司产品。
2试验方法
2.1剂量设计：受试品以0.15g/1cm2、0.1g/1cm2、0.05g/1cm2局部涂抹作为大剂量、中剂量组和小剂量组。空白对照组和模型对照组给予0.1g/1cm2蒸馏水局部涂抹。
2.2皮肤过敏实验
取大鼠36只，雌性，室温环境下分笼饲养，自由取食及摄水，适应性饲养5天后按体重随机分组，分别为空白对照组、模型对照组、受试品大剂量组、中剂量组和小剂量组，每组6只。背部剃毛后，除空白对照组外，其余各组大鼠背部选取3个点，每点皮下注射anti-DNP IgE 0.5μg(0.5μl)。48小时后，各组大鼠尾静脉注射含有4％伊文思蓝的DNP-HAS 100μg(100μl)。在尾静脉注射DNP-HAS前1小时，在给药各组大鼠背部，以注射anti-DNP IgE的点为中心，每点涂抹2cm2面积的相应药物。静脉注射DNP-HAS后30分钟处死大鼠。剪下蓝染皮肤，使用1:1丙酮-生理盐水混合溶液浸泡24h，离心取上清，用分光光度计于620nm处检测OD值。使用伊文思蓝溶液制作标准曲线，计算每只大鼠背部皮肤染料含量及PCA反应抑制率。抑制率计算公式如下：
Figure PCTCN2016076485-appb-000017
3试验结果
结果显示，致敏后大鼠局部皮肤蓝染，使用受试品涂抹后，受试品可显著降低大鼠蓝染皮肤染料含量，与模型对照组比较均有显著性差异或极显著差异(P<0.01，P<0.05)，结果见表10。
表10样品对大鼠PCA反应的影响
Figure PCTCN2016076485-appb-000018
Figure PCTCN2016076485-appb-000019
4试验结论
实施例1制备纤体提取物、实施例4制备所得纤体膏霜显著降低致敏大鼠蓝染皮肤染料含量，说明本发明制剂具有潜在的消除外援刺激引起的红肿功效。
发明人用实施例2、实施例3、实施例5、实施例6制备制剂重复上述实验，得到相同的效果，与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P＞0.05)。
六、实施例1制备组合物、实施例4制备膏霜抗疲劳功效评价
近年来，由于久坐不动、过度的脑力劳动引起的慢性疲劳成为办公室工作者常见问题，主要表现为肩胛、脖颈等的疼痛及不适，这严重影响了人们的工作效率及生活质量。用本实施例制备样品在抗疲劳功效方面进行评价，评价方法如下：
实验样品：实施例1所得植物组合物、实施例4所得膏霜；
实验对象：30名具有脖颈疼痛症状的办公室工作人员，随机分为两组，每组15人，分别试用实施例1制备组合物、实施例4制备膏霜；
使用方法：脖颈等酸痛处涂抹、按摩，每天2次，早晚各一次，持续4周。
评价标准：疗效显著：疼痛症状消失；症状缓解：疼痛症状减轻；无效：试用前后无明显变化；有效：疗效显著和症状缓解；
对30名试用者的使用结果统计如表11：
表11样品抗疲劳试用效果评价
  显著 缓解 无效 有效率(％)
实施例1 2 6 7 53％
实施例4 3 7 5 67％
评价结果表明，本发明制备组合物及膏霜制剂均具有舒缓酸痛感、抗疲劳的功效，用实施例2、实施例3、实施例5、实施例6制备得样品重复上述，得到相同的结果，与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P＞0.05)。
七、实施例1及实施例4制备所得制剂活血功效评价
实验方法
实验样品：实施例1所得植物提取物、实施例4所得膏霜。
涂抹方式：小腿、小臂涂抹，每天2次，早晚各一次，持续4周。
评价方法：护肤品的活血滋养功效可通过红外热成像图评价。皮肤的红外热成像图可以检测到受试部位血流速度及温度，可以反映气血运行情况，血流速度快、温度 高，则气血好。通过对比试用前后的红外成像图可评价样品的活血效果。实施例1制备组合物对小腿、小臂红外成像如图1、图2所示，实施例4制备膏霜对小腿、小臂红外成像如图3、图4所示。皮肤红外热成像结果显示，试用者在使用样品后(如图1(B)、图2(B)、图3(B)、图4(B)所示)，皮肤的血流速度提升(图中，受试部位颜色偏淡的部位，血流速度快)。
红外热成像实验证实，实施例1、实施例4所得样品具有良好的促进血液循环功效，对实施例2、实施例3、实施例5及实施例6制备所得样品进行同样的试验，结果同上，与实施例1制备纤体提取物、实施例4制备所得纤体膏霜无显著差异(P＞0.05)。
以上对本发明所提供的一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法进行了详细介绍。本文应用了具体个例对本发明的原理及实施方式进行了阐述，以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出，对于本技术领域技术人员来说，在不脱离本发明原理的前提下，还可以对本发明进行若干改进和修饰，这些改进和修饰也落入本发明权利要求的保护范围内。

Claims (10)

  1. Figure PCTCN2016076485-appb-100001
    所述制备方法包括如下步骤：
    步骤1：将A相加热、搅拌，获得第一产品；
    步骤2：将B相加热、搅拌，获得第二产品；
    步骤3：将所述第一产品与第二产品混合，乳化，获得第三产品；
    步骤4：将C相与所述第三产品混合，获得第四产品；
    步骤5：取所述第四产品，搅拌、降温，加入D相、E相、F相，混合，冷却，即得。
  2. 根据权利要求7所述的制备方法，其特征在于，步骤1中所述加热的温度为80～85℃，所述加热的升温速率为1～2℃/min；所述加热的时间为30～35min；步骤1中所述搅拌的速率为20～60r/min；
    步骤2中所述加热的温度为80～85℃，所述加热的升温速率为1～2℃/min；所述加热的时间为30～35min；步骤1中所述搅拌的速率为20～60r/min；
    步骤3中所述混合的搅拌速率为30～50r/min；所述乳化为在2500～3500r/min的条件下均质乳化3～5min；
    步骤4中所述混合的搅拌速率为30～50r/min；
    步骤5中所述搅拌的速率为30～50r/min；所述降温的温度为40～50℃，所述降温的速率为1～2℃/min；
    步骤5中所述冷却的温度为30℃～40℃。
  3. 根据权利要求7或8所述的制备方法制得的护肤品。
  4. 一种组合物，其特征在于，包括如下质量份的原料：
    Figure PCTCN2016076485-appb-100002
  5. 根据权利要求1所述的组合物的制备方法，其特征在于，取配方量的所述原料粉碎后，水提；所述水提的温度为61℃～100℃，所述水提的时间为1～4h；所述水提的原料与水的质量比为1∶21～1∶40。
  6. 根据权利要求1所述的组合物或根据权利要求2所述的制备方法制得的组合物在制备纤体、护肤的药物、食品、保健品和/或护肤品中的应用。
  7. 根据权利要求1所述的组合物或根据权利要求2所述的制备方法制得的组合物在制备提高脂肪细胞瘦素分泌水平、治疗皮肤瘙痒、皮肤修复、去除红肿、抗疲劳、活血、促进胶原蛋白合成的药物、食品、保健品和/或护肤品中的应用。
  8. 一种护肤品，其特征在于，包括如权利要求1所述的组合物或根据权利要求2所述的制备方法制得的组合物和护肤品中可接受的辅料。
  9. 根据权利要求5所述的护肤品，其特征在于，所述护肤品的剂型为膏剂、霜剂、精华、爽肤水、乳液或喷雾剂。
  10. 根据权利要求5或6所述的护肤品的制备方法，其特征在于，其由如下质量份的原料制成：
    Figure PCTCN2016076485-appb-100003
PCT/CN2016/076485 2015-08-24 2016-03-16 一种纤体护肤的组合物及其制备方法 WO2017031981A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/746,408 US20180200181A1 (en) 2015-08-24 2016-03-16 Composition for body slimming and skin care and preparation method thereof
EP16838244.8A EP3342417B1 (en) 2015-08-24 2016-03-16 Composition for body slimming and skin care and preparation method thereof
JP2018506987A JP2018522923A (ja) 2015-08-24 2016-03-16 痩身ならびにスキンケア用組成物、および、その調製方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510527307.1A CN106691904A (zh) 2015-08-24 2015-08-24 一种组合物及其制备方法和用途、含有该组合物的护肤品及其制备方法
CN201510527307.1 2015-08-24

Publications (1)

Publication Number Publication Date
WO2017031981A1 true WO2017031981A1 (zh) 2017-03-02

Family

ID=58099363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/076485 WO2017031981A1 (zh) 2015-08-24 2016-03-16 一种纤体护肤的组合物及其制备方法

Country Status (5)

Country Link
US (1) US20180200181A1 (zh)
EP (1) EP3342417B1 (zh)
JP (1) JP2018522923A (zh)
CN (1) CN106691904A (zh)
WO (1) WO2017031981A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019168292A (ja) * 2018-03-22 2019-10-03 株式会社 資生堂 レプチンを指標とする肌色悪化リスク評価方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974751A (zh) * 2019-12-31 2020-04-10 武汉洛园生物科技有限公司 一种纤体瘦身化妆品组合物及其制作方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224603A (zh) * 2013-06-23 2014-12-24 青岛道合生物科技有限公司 一种植物抗氧化爽肤水

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3441215B2 (ja) * 1995-03-01 2003-08-25 花王株式会社 入浴剤組成物
JPH09295932A (ja) * 1996-05-02 1997-11-18 Nonogawa Shoji Kk 化粧料用痩身剤組成物
US6464991B1 (en) * 1999-05-04 2002-10-15 Finetex, Inc. Oat lipid based surfactants and derivatives and process for preparing same
FR2802811B1 (fr) * 1999-12-24 2002-02-15 Silab Sa Procede d'extraction d'un principe actif a partir de petales de bigarade, notamment pour le traitement de la cellulite, principe actif obtenu, compositions cosmetiques et traitements adaptes
JP2003286129A (ja) * 2002-03-27 2003-10-07 Hakugen:Kk 痩身シート材
JP2004059545A (ja) * 2002-07-31 2004-02-26 Noevir Co Ltd ヒスタミンｈ１受容体遮断剤
JP4034681B2 (ja) * 2003-03-28 2008-01-16 リンナイ株式会社 ガラストップコンロ
JP2004307365A (ja) * 2003-04-03 2004-11-04 Kao Corp 脂肪分解促進剤
JP4691320B2 (ja) * 2003-12-26 2011-06-01 株式会社資生堂 脂肪蓄積抑制用組成物
CN1268221C (zh) * 2004-07-01 2006-08-09 汕头市生奥保健食品有限公司 一种蔬果花草茶及其制作方法
CN1298230C (zh) * 2004-09-21 2007-02-07 邓运林 绿色生态保健茶及其生产方法
JP4634768B2 (ja) * 2004-10-04 2011-02-16 独立行政法人産業技術総合研究所 皮膚老化防止効果向上剤、その製造方法、それを用いた皮膚老化防止用組成物及びそれを含有する皮膚外用剤。
CN101766556A (zh) * 2008-12-31 2010-07-07 云南恒冠实业有限公司 一种纤体瘦身化妆品组合物
FR2946529B1 (fr) * 2009-06-10 2011-09-09 Lvmh Rech Utilisation d'un extrait de cereale, en tant qu'agent actif amincissant dans une composition cosmetique amincissante
CN101856390B (zh) * 2010-06-01 2012-05-23 苏风顺 一种纤体中药膏剂
CN103621993A (zh) * 2012-08-28 2014-03-12 浙江劲膳美生物科技有限公司 一种气虚食疗配餐或代餐品
CN104286657A (zh) * 2014-09-28 2015-01-21 赵敬哲 一种水果养颜粥及其制备方法
CN104286658A (zh) * 2014-09-29 2015-01-21 刘韶娜 一种减肥粥及其制备方法
CN104473045A (zh) * 2014-11-11 2015-04-01 明光市白云面粉有限公司 一种适合三高人群的保健米粉及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224603A (zh) * 2013-06-23 2014-12-24 青岛道合生物科技有限公司 一种植物抗氧化爽肤水

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU, LI: "Cream of Traditional Chinese Herbal Cuisine: a Complete Collection of Herbal Cuisine for Cosmetology", CHINA MEDICAL SCIENCE PRESS, 30 April 2012 (2012-04-30), pages 62, XP 009510249 *
WANG, JIANXIN: "Cosmetic Plant Raw Materials Manual", CHEMICAL INDUSTRY PRESS, 30 June 2009 (2009-06-30), pages 323 - 324, XP009509166 *
ZHANG, LIPING;: "New Research Progress On Tangerine Peel", GUANGMING JOURNAL OF CHINESE MEDICINE, vol. 20, no. 1, 28 February 2005 (2005-02-28), pages 41, XP 009509161 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019168292A (ja) * 2018-03-22 2019-10-03 株式会社 資生堂 レプチンを指標とする肌色悪化リスク評価方法
JP7214356B2 (ja) 2018-03-22 2023-01-30 株式会社 資生堂 レプチンを指標とする肌色悪化リスク評価方法

Also Published As

Publication number Publication date
US20180200181A1 (en) 2018-07-19
EP3342417A1 (en) 2018-07-04
CN106691904A (zh) 2017-05-24
EP3342417A4 (en) 2019-02-27
JP2018522923A (ja) 2018-08-16
EP3342417B1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
CN105769654B (zh) 一种舒敏护肤组合物及其在化妆品中的应用
JP4693963B2 (ja) エストロゲン様作用剤、コラーゲン産生促進剤、及び線維芽細胞増殖剤
KR100813781B1 (ko) 아토피 피부염 개선능을 갖는 한방 조성물 및 그 제조방법
KR101908978B1 (ko) 스트레스 완화 및 피로 회복 효과를 갖는 향료 조성물 및 이를 함유하는 화장료 조성물
CN104147533A (zh) 一种活血化瘀止痛乳膏及其制备方法
KR20150006639A (ko) Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물
CN103877247B (zh) 用于治疗褥疮的药物及其制备方法
WO2017031981A1 (zh) 一种纤体护肤的组合物及其制备方法
CN104784297B (zh) 一种抗皮肤过敏组合物
CN108635326A (zh) 一种含有石斛干细胞提取物抗衰老祛皱组合物及其用途
CN111643610A (zh) 一种植物复合液及其制备方法和应用
CN110025705A (zh) 一种治疗特应性皮炎的中药组合物及其制备方法和应用
KR100991309B1 (ko) 탈모방지 및 모발생장 촉진용 한방 조성물 및 그 제조방법
CN113576970A (zh) 一种抗衰老植物提取组合物及其制备与应用
TW202128029A (zh) 蒲公英萃取物用於製備促進脂肪代謝及水份代謝的組合物之用途
CN110812411A (zh) 一种外用抗过敏治疗皮肤湿疹的参柏草精油
CN108452205A (zh) 一种治疗痛经的含有沉香精油的痛经贴及其制备方法
CN114053329B (zh) 构树花多糖在制备防治紫外损伤的药物或者防晒化妆品中的应用
CN114209633B (zh) 一种抗炎舒敏修复组合物及其制备方法和应用
CN107158205B (zh) 一种治疗高血压的药物组合物
Ali et al. A Comparison of Preventive Effects of Punica Granatum and Extract on Weight and Volume of Steroid Induced Mice Kidney: Protective Effects of Two Forms of Pomegranate
CN104784587A (zh) 一种治疗内分泌失调型不孕的中药组合物及其制备方法
KR20150070514A (ko) 혼합 생약재 추출물을 유효성분으로 함유하는 섬유아세포 증식 및 스트레스로 인한 탈모의 예방 또는 개선용 조성물
CN104208315A (zh) 一种治疗白内障的滴眼液
CN113559182A (zh) 一种具有补血益气、减肥功效的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16838244

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15746408

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2018506987

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE